ClinicalTrials.gg
CompletedNCT04563026AHFIRMUpdated Sep 5, 2024

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

A Phase 2 interventional study of DUR-928 30 mg and DUR-928 90 mg in Alcoholic Hepatitis, sponsored by Durect. Completed at 68 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Hepatitis, Alcoholic with a site in United States — 7 open to participants now, 7 under way, 1 of them phase 3. Hepatitis, Alcoholic · United States.

Enrollment
2nd of 28
307 · median 44
Started
2021
with 2 others
Phase 2
17 of 38
none open now
Registered
31st of 38
by date
Lead sponsor
2 of 38
Durect

Among the 38 studies in Hepatitis, Alcoholic with a site in United States, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2021, is one of 17 in phase 2, and was the 31st registered.

Hepatitis, Alcoholic

114 studies on the registry are indexed under Hepatitis, Alcoholic; 25 are open to participants now.

Browse Hepatitis, Alcoholic studies →

Open to participants now

7 of the 38 studies in Hepatitis, Alcoholic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Hepatitis, Alcoholic studies recruiting now, 9 (53%) set no upper age limit and 8 (47%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Hepatitis, Alcoholic with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).

03

Conditions studied

  • Alcoholic Hepatitis

Browse trials for

Keywords

  • Alcoholic Hepatitis
  • acute alcoholic liver disease
  • progressive inflammatory liver injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written (either from subject or subject's legally acceptable representative).
  2. Onset of jaundice within prior 8 weeks.
  3. Average daily consumption of >40 (females) or >60 (males) grams of alcohol for 6 months or longer, with \< 8 weeks of abstinence before the onset of jaundice.
  4. The determination of AH may be based on typical serum chemistry (as determined by local laboratory) or liver at any time during the current episode of AH:

    • Serum total > 3.0 mg/dL
    • 50 \< \< 400 IU/L
    • ALT \< 400 IU/L
    • AST/ALT > 1.5
  5. Maddrey discriminant function (MDF) ≥ 32 assuming a control of 12 seconds.
  6. Model for End-stage Liver Disease (MELD) score: 21-30.
  7. Liver biopsy is not required, but may be used to confirm the diagnosis of AH at the Investigator's discretion. Biopsy, if used as a diagnostic criterion, must have occurred during the current episode.
  8. Male or female subjects 18 years of age or older.
  9. Subjects must agree to use effective methods to prevent pregnancy while participating in the study.
  10. Subjects must agree to participate in an alcohol abstinence support program recommended by the local institution's addiction specialists.

Exclusion criteria

Exclusion Criteria:

  1. Subjects taking systemic for a duration exceeding 8 days in the 30 days prior to screening.
  2. Subjects experiencing or considered at high risk for alcohol withdrawal seizures or delirium tremens.
  3. Active infection (such as spontaneous bacterial peritonitis [SBP], urinary tract infection [UTI], bacteremia, acute viral hepatitis, uncontrolled , and active SARS CoV2 infection).
  4. Serum creatinine >2.5 mg/dL.
  5. Subjects undergoing continuous veno-venous hemodialysis (CVVH).
  6. Uncontrolled gastrointestinal bleeding.
  7. A history of pre-admission ascites defined as more than 4 paracenteses in the previous 8 weeks despite diuretic therapy.
  8. Liver (if carried out) with findings not compatible with AH.
  9. Stage ≥3 hepatic encephalopathy by West Haven criteria.
  10. Any severe concomitant cardiovascular, renal, endocrine, pulmonary, psychiatric disorder, or multi-organ failure.
  11. Other concomitant cause(s) of liver disease.
  12. Any active or any malignancy diagnosed within the last five years other than curable skin cancer (basal cell or squamous cell carcinomas).
  13. Positive Urine Drug Screen (amphetamines, barbiturates, benzodiazepines, cocaine and opiates) except THC and prescription medications.
  14. Existing or intended pregnancy or breast feeding.
  15. Participation in another interventional clinical trial within 30 days of Screening.
  16. History of organ transplantation, other than a corneal transplant.
  17. Underlying diseases that, in the opinion of the site investigator, might be complicated or exacerbated by proposed treatments or might confound assessment of study drug.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    DUR-928 (larsucosterol, 30 mg)

    Drug: DUR-928 30 mg

  • Experimental
    DUR-928 (larsucosterol, 90 mg)

    Drug: DUR-928 90 mg

  • Placebo comparator
    (Placebo) Sterile Water for Injection

    Drug: Placebo+ Standard of Care (SOC)

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in 90-day mortality or liver transplant between IV DUR-928, 30 mg or 90 mg, and placebo.

    Time frame: Day 90

Secondary outcomes

  1. Difference in 90-day mortality between IV DUR-928, 30 mg or 90 mg, and placebo.

    Time frame: Day 90

  2. Difference in 28-day mortality or liver transplant between IV DUR-928, 30 mg or 90 mg, and placebo.

    Time frame: Day 28

  3. Difference in 28-day mortality between IV DUR-928, 30 mg or 90 mg, and placebo.

    Time frame: Day 28

07

Study locations

68 sites
  • University of Alabama at Birmingham (UAB) Hospital
    Birmingham, Alabama 35233, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Keck Hospital of University of Southern California (USC)
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California Davis (UC Davis) Medical Center
    Sacramento, California 95817, United States
  • University of California San Francisco (UCSF) Medical Center
    San Francisco, California 94143, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • MedStar Health - MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Richard Roudebush VA Hospital
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • University of Minnesota Medical School
    Minneapolis, Minnesota 55455, United States
  • Saint Luke's Health System - Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center (UNMC)
    Omaha, Nebraska 68198, United States
  • Rutgers-New Jersey Medical School
    Newark, New Jersey 07103, United States
  • University of New Mexico (UNM) Hospital
    Albuquerque, New Mexico 87106, United States
  • Northwell Health - North Shore University Hospital
    Manhasset, New York 11030, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • New York-Presbyterian - Weill Cornell Medical Center
    New York, New York 10065, United States
  • Atrium Health
    Charlotte, North Carolina 28204, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Medical University of South Carolina (MUSC) Health - University Medical Center
    Charleston, South Carolina 29425, United States
  • Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Parkland Memorial Hospital
    Dallas, Texas 75235, United States
  • Baylor Scott and White Health
    Dallas, Texas 75246, United States
  • University of Texas Southwestern (Clements University Hospital)
    Dallas, Texas 75390, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Doctors Hospital at Renaissance (DHR)
    Edinburg, Texas 78539, United States
  • Baylor College of Medicine Medical Center
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Utah Health - The University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • University of Virginia (UVA) Health - University Hospital
    Charlottesville, Virginia 22908, United States
  • Bon Secours Liver Institute of Richmond
    Richmond, Virginia 23226, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
  • Harborview Medical Center - University of Washington
    Seattle, Washington 98104, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2217, Australia
  • Mater Health - Mater Hospital Brisbane
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Eastern Health - Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Landeskrankenhaus (LKH) - Universitätsklinikum Graz
    Graz, 8036, Austria
  • Université libre de Bruxelles (ULB) - Hôpital Erasme
    Brussels, 1070, Belgium
  • Universitair Ziekenhuis Antwerpen (UZA)
    Edegem, 2650, Belgium
  • Centre Hospitalier Régional Universitaire (CHRU) Besançon - Hôpital Jean Minjoz
    Besançon, 25000, France
  • Centre Hospitalier Universitaire (CHU) de Lille - Hôpital Jeanne de Flandre
    Lille, 59037, France
  • Hospices Civils de Lyon - Hôpital de la Croix-Rousse
    Lyon, 69004, France
  • Hôpital St Joseph
    Marseille, 13008, France
  • Barts Health NHS Trust - The Royal London Hospital
    London, England E1 1FR, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, England SE5 9RS, United Kingdom
  • Imperial College Healthcare NHS Trust - St. Mary's Hospital
    London, England W2 1NY, United Kingdom
  • University Hospitals Plymouth NHS Trust - Derriford Hospital
    Plymouth, England PL6 8DH, United Kingdom
  • Royal Free London NHS Foundation Trust Hospital
    London, NW3 2QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Sep 2023, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 24, 2020
StartActual
Jan 22, 2021
Primary completionActual
Sep 6, 2023
CompletionActual
Sep 6, 2023
Results delay requested
Sep 3, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04563026
Lead sponsor
Durect
Collaborators
CTI Clinical Trial and Consulting Services
Responsible party
Sponsor
First posted
Sep 24, 2020
Start date
Jan 22, 2021
Primary completion
Sep 6, 2023
Completion
Sep 6, 2023
Last update
Sep 5, 2024

Study contacts

Robert Gordon, MD, FACS
study director · CTI Clinical Trial and Consulting Services

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larsucosterol

Start the discussion